Showing results (131-140 of 200) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR studyChristophe Tournigand, Andres Cervantes, Arie Figer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2007
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors TrialEduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España, et al.
The Oncologist|April 28, 2018
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabAsunción Díaz-Serrano, Barbara Angulo, Carolina Dominguez, et al.
International Journal of Colorectal Disease|February 17, 2020
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?Ruth Vera, Elena Mata, Encarna González, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2024
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidednessTakayuki Yoshino, Naushin Hooda, Diana Younan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation studyJosep Tabernero, Andres Cervantes, Fernando Rivera, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 27, 2016
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJavier Salvador, Jorge Aparicio, Francisco Javier Baron, et al.
Gastroenterologia Y Hepatologia|January 16, 2024
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCUMar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, et al.
Revista Espanola De Enfermedades Digestivas|January 16, 2024
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCUMar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, et al.
Investigational New Drugs|October 21, 2010
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasoneLuis Paz-Ares, Antonio López-Pousa, Andrés Poveda, et al.
Pageof 20